Our work indicates that the potential targeting of the Drd2-associated mPFC-BLA neural circuit may serve as a therapeutic strategy in alleviating the cognitive deficits that commonly occur in sleep disorder patients. The gene discussed is DRD2; the disease is sleep disorder.